A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 492 participants.

Also called NCT01558271

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 492 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01558271
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01558271. Randomized; quadruple masking; primary purpose treatment. Start 2012-03 (registry gives no type); primary completion 2013-10 (actual). Results posted on 2014-10-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
LY2189265
Intervention (Drug)
Placebo
Intervention (Drug)
Liraglutide
Lead sponsor
Eli Lilly and Company (class: industry)

Record details

Record id
cardio:ct-nct01558271
Content hash
d7005909dc5439f6a18881ee8c5ee3a47fd7abe2335f784361dcb8b430158a62